Evaluation of antibiotic-induced taste and smell disorders using the FDA adverse event reporting system database.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
05 05 2021
Historique:
received: 24 08 2020
accepted: 20 04 2021
entrez: 6 5 2021
pubmed: 7 5 2021
medline: 25 2 2023
Statut: epublish

Résumé

Adverse effects can occur owing to anorexia, which can reduce treatment compliance and worsen the patients overall condition. One such side effect, namely drug-induced taste and smell disorders, reduces patients quality of life. Although antibiotics can cause taste and smell disorders, a few studies have examined antibiotic-induced taste and smell disorders. Therefore, this study comprehensively analyzed the relationship between taste and smell disorders and antibiotic usage. The side effects of antibiotics were investigated using the FDA Adverse Event Reporting System database (FAERS). The reporting odds ratios between the listed drugs and taste and smell disorders P values were comprehensively calculated. Adjusted odds ratios were calculated to account for patient background. Furthermore, to clarify the feature of this adverse effect, shape parameters indicating the expression pattern were calculated. Signals that induced taste and smell disorders were detected for six antibiotics, including drugs for which this event is not described in the package insert in Japan. Multiple logistic regression analysis suggested an association of taste and smell disorders with gender, hypertension, mental disorder, and cancer. The median time to onset of antibiotic-induced taste and smell disorders was 2-5 days. Six antibiotics could be analyzed, and four of these drugs matched those with detected signals. Our study supported previous findings on gender and age. Furthermore, antibiotic-induced taste and smell disorders are likely to develop in the early stage of treatment. For these reasons, it is important to remember the risk of developing of taste and smell disorders when administering antibiotics. In addition, it is recommended that the patient be monitored carefully for at least 1 week before initiating treatment, and the patients course should be followed for at least 2 months.

Identifiants

pubmed: 33953272
doi: 10.1038/s41598-021-88958-2
pii: 10.1038/s41598-021-88958-2
pmc: PMC8100100
doi:

Substances chimiques

Anti-Bacterial Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

9625

Références

J Pharm Health Care Sci. 2017 Jul 19;3:19
pubmed: 28729910
Int J Med Sci. 2017 Jan 15;14(2):102-109
pubmed: 28260984
Front Physiol. 2019 May 31;10:652
pubmed: 31214042
Biol Pharm Bull. 2015;38(5):680-6
pubmed: 25947914
Support Care Cancer. 2020 Mar;28(3):1173-1181
pubmed: 31203507
Oral Health Prev Dent. 2018;16(6):499-507
pubmed: 30574604
J Pharm Health Care Sci. 2015 Dec 22;1:34
pubmed: 26819745
BMJ Open. 2016 Nov 9;6(11):e013246
pubmed: 28157672
Biol Pharm Bull. 2017;40(12):2158-2165
pubmed: 29199239
Drug Saf. 2011 Oct 1;34(10):849-59
pubmed: 21879779
PLoS One. 2017 Feb 14;12(2):e0172057
pubmed: 28196104
Drug Saf. 2008;31(3):199-215
pubmed: 18302445
Yakugaku Zasshi. 2016;136(3):507-15
pubmed: 26935094
J Laryngol Otol. 2008 Feb;122(2):155-60
pubmed: 17592661
Yakugaku Zasshi. 2018;138(4):559-564
pubmed: 29608006
Biol Pharm Bull. 2019;42(7):1185-1191
pubmed: 31257293
J Pharm Health Care Sci. 2019 Sep 2;5:20
pubmed: 31497309
Nihon Jibiinkoka Gakkai Kaiho. 2013 Feb;116(2):77-82
pubmed: 23539955
J Pharm Health Care Sci. 2016 Jun 21;2:14
pubmed: 27330825
Laryngoscope Investig Otolaryngol. 2018 Feb 21;3(2):94-99
pubmed: 29721540
Am J Med. 2016 Jul;129(7):753.e1-6
pubmed: 26899755
J Clin Pharmacol. 1991 Feb;31(2):164-7
pubmed: 1849152
PLoS One. 2015 Dec 07;10(12):e0144263
pubmed: 26641634
Nihon Yakurigaku Zasshi. 2006 Jun;127(6):447-53
pubmed: 16880694
Int J Clin Pharm. 2020 Apr;42(2):721-727
pubmed: 32270377

Auteurs

Yusuke Kan (Y)

Department of Medical Molecular Informatics, Meiji Pharmaceutical University, Tokyo, 204-8588, Japan.
Nanohana Pharmacy, Tokyo, 196-0014, Japan.

Junko Nagai (J)

Department of Medical Molecular Informatics, Meiji Pharmaceutical University, Tokyo, 204-8588, Japan.

Yoshihiro Uesawa (Y)

Department of Medical Molecular Informatics, Meiji Pharmaceutical University, Tokyo, 204-8588, Japan. uesawa@my-pharm.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH